Ralexar Therapeutics, Inc. — Form D/A

Ralexar Therapeutics, Inc. of Encinitas, CA, a company, filed a Form D amendment with the SEC on 2020-04-01. The offering totals $6.0M, of which $4.3M was reported sold. Industry: Pharmaceuticals.

Offering

Filed: 2020-04-01
Form: D/A
Accession: 0001596494-20-000001
Industry: Pharmaceuticals
Exemptions: 06b
Total offering: $6.0M
Amount sold: $4.3M
Remaining: $1.7M
Investors: 11
Date of first sale: 2018-12-20
Security types: equity
Revenue range: Decline to Disclose
SEC file number: 021-329633

Issuer

Name: Ralexar Therapeutics, Inc.
CIK: 0001596494
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2013
Address: 662 Encinitas Blvd., Encinitas, CA, 92024
Phone: 484-318-2988

Officers, directors & promoters (11)

Name	Role	Location
JASON HONG	Director	STAMFORD, CT
David Pfeiffer	Director	Wayne, PA
Somasundaram Subramaniam	Director	San Diego, CA
Stephen Tullman	Director	Malvern, PA
Neal Walker	Director	Malvern, PA
David Pfeiffer	Executive Officer	Wayne, PA
Stephen Tullman	Executive Officer	Malvern, PA
Somu Subramaniam	Director	South San Francisco, CA
Raju Mohan	Executive Officer	San Diego, CA
Kamil Ali-Jackson	Executive Officer	Wayne, PA
Douglas Gessl	Executive Officer	Wayne, PA

Other filings by this issuer (4)

Filed	Form	Offering	Sold
2019-01-04	D	$6.0M	$1.9M
2017-06-08	D	$6.9M	$4.1M
2015-04-28	D/A	$21.5M	$10.6M
2014-01-10	D	$21.5M	$5.2M

More